NATURE REVIEWS DRUG DISCOVERY

Scope & Guideline

Pioneering insights into the world of drug discovery.

Introduction

Delve into the academic richness of NATURE REVIEWS DRUG DISCOVERY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1474-1776
PublisherNATURE PORTFOLIO
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2002 to 2024
AbbreviationNAT REV DRUG DISCOV / Nat. Rev. Drug Discov.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressHEIDELBERGER PLATZ 3, BERLIN 14197, GERMANY

Aims and Scopes

Nature Reviews Drug Discovery is dedicated to providing comprehensive reviews and insights into the evolving landscape of drug discovery and development. The journal's primary focus lies in facilitating a deeper understanding of the scientific and technological advancements that shape the pharmaceutical industry.
  1. Drug Discovery Mechanisms:
    The journal extensively covers the mechanisms underlying drug discovery, including target identification, lead optimization, and preclinical development, highlighting innovative methodologies and technologies.
  2. Therapeutic Areas:
    Nature Reviews Drug Discovery addresses a wide range of therapeutic areas, including oncology, neurology, infectious diseases, and autoimmune disorders, providing insights into current trends and future directions in these fields.
  3. Emerging Technologies:
    The journal emphasizes the role of emerging technologies in drug discovery, such as artificial intelligence, gene editing, and novel drug delivery systems, showcasing how these innovations can enhance drug development processes.
  4. Clinical Development and Regulatory Landscapes:
    The journal discusses the challenges and strategies associated with clinical trials and regulatory approvals, offering critical analyses of recent FDA approvals and the implications for drug development.
  5. Personalized Medicine and Precision Therapeutics:
    Nature Reviews Drug Discovery explores the advancements in personalized medicine, focusing on how genetic and molecular profiling can inform drug development and improve patient outcomes.
Recent publications in Nature Reviews Drug Discovery reveal several emerging themes and trends that reflect the current priorities and interests of the drug discovery community.
  1. Artificial Intelligence in Drug Discovery:
    The integration of AI and machine learning in drug discovery processes is rapidly increasing, with a focus on improving target identification, predictive modeling, and optimizing drug design.
  2. Gene Therapy and Genetic Medicines:
    There is a growing emphasis on gene therapy approaches, including CRISPR and RNA-based therapies, which are seen as revolutionary methods for treating genetic disorders and complex diseases.
  3. Immunotherapy Innovations:
    The field of immunotherapy is witnessing significant advancements, particularly in CAR-T cell therapies and bispecific antibodies, which are becoming key areas of research in oncology.
  4. Microbiome Research in Drug Development:
    The role of the microbiome in drug metabolism and therapeutic efficacy is gaining attention, leading to new strategies for drug development that consider microbiome interactions.
  5. Regenerative Medicine and Tissue Engineering:
    Emerging research on regenerative medicine and tissue engineering is highlighting novel therapeutic strategies for treating degenerative diseases and injuries, marking a shift towards more holistic treatment approaches.

Declining or Waning

As the field of drug discovery evolves, certain themes and areas of focus may decline in prominence. Recent analyses indicate a waning interest in specific topics that were previously prominent in the literature.
  1. Traditional Small Molecule Drug Discovery:
    While still relevant, there has been a noticeable shift towards biologics, gene therapies, and advanced therapeutic modalities, leading to a decline in the emphasis on traditional small molecule approaches.
  2. Conventional Monoclonal Antibodies:
    The exploration of conventional monoclonal antibodies is decreasing, as the field moves towards bispecific antibodies, antibody-drug conjugates, and other innovative formats that offer improved efficacy and specificity.
  3. Single-Target Approaches:
    The focus on single-target drug discovery is declining in favor of multi-target strategies that consider the complexity of diseases, particularly in oncology and chronic conditions.
  4. Standard Clinical Trial Designs:
    There is a diminishing focus on traditional clinical trial designs, with increasing interest in adaptive trial designs and real-world evidence to better evaluate drug efficacy and safety.
  5. Cytokine-Based Therapies:
    Interest in cytokine-based therapies appears to be waning, as researchers explore more targeted and less toxic immunotherapeutic options.

Similar Journals

Discovery Medicine

Empowering the medical community with cutting-edge findings.
Publisher: DISCOVERY MEDICINEISSN: 1539-6509Frequency: 6 issues/year

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

Future Journal of Pharmaceutical Sciences

Pioneering Discoveries in Drug Development and Therapeutics
Publisher: SPRINGERISSN: 2314-7245Frequency: 1 issue/year

The Future Journal of Pharmaceutical Sciences, published by Springer, stands as a vital resource in the realm of pharmaceutical research and innovation. Recognized for its open access initiative since 2015, this journal promotes extensive dissemination of cutting-edge discoveries, fostering collaboration among researchers, industry professionals, and students alike. With an ISSN of 2314-7245 and an E-ISSN of 2314-7253, it aims to bridge the gap between laboratory research and practical applications in the pharmaceutical sciences. Although specific metrics like HIndex and Scopus ranks are currently unavailable, the journal's commitment to high-quality, peer-reviewed content positions it as a promising platform for advancing pharmaceutical science. By engaging with this journal, contributors and readers can participate in the vibrant discourse shaping the future of drug development, therapeutic strategies, and healthcare solutions.

SCIENTIA PHARMACEUTICA

Advancing pharmaceutical science for a healthier tomorrow.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

Clinical Pharmacology in Drug Development

Exploring the future of drug efficacy and safety.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

MEDICINAL RESEARCH REVIEWS

Transforming Research into Revolutionary Therapeutics
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

Pharmaceutical Sciences

Pioneering research at the intersection of science and health.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Advancing pharmacological knowledge for better patient care.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

DRUG DISCOVERY TODAY

Advancing the Frontiers of Drug Discovery
Publisher: ELSEVIER SCI LTDISSN: 1359-6446Frequency: 12 issues/year

DRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.

Advances in Pharmacological and Pharmaceutical Sciences

Bridging Research and Practice in Pharmaceutical Sciences.
Publisher: HINDAWI LTDISSN: 2633-4682Frequency: 1 issue/year

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

CLINICAL THERAPEUTICS

Elevating patient care with cutting-edge pharmacological insights.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.